Octapharma Partners With Apexus to Provide IGIV at Sub-340B Price

by admin | August 1, 2012 3:00 pm

August 1, 2012—Octapharma USA’s octagam 5% immune globulin intravenous (IGIV) therapy is now available at sub-340B pricing to participants in the Apexus/340B Prime Vendor Program (PVP).

Apexus Director of Contract Services John Barnes made the announcement in a July 30 email to PVP participants.[ms-protect-content id=”2799″] “It has taken nearly eight years, but we have finally secured a contract for [IVIG] at sub-340B pricing,” he wrote. “Octapharma has confirmed to Apexus there are no restrictions or allocations placed on octagam at sub-340B pricing.” The company, he added, intends to add its octagam 10% IGIV therapy to the Apexus portfolio if it is approved by the Food and Drug Administration.

In late June, Octapharma announced an initiative[1] to make octagam 5% widely available to 340B covered entities, which have long been unable to obtain IGIV products at 340B prices.[2]

Swiss-based Octapharma is one of only four major blood-plasma product companies[3] in the U.S. market. The others are Baxter, Grifols, and CSL Behring.[/ms-protect-content]

 

Source URL: https://340bemployed.org/octapharma-partners-with-apexus-to-provide-igiv-at-sub-340b-price/

---